Keyphrases
High Risk
100%
Novel Therapeutics
100%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
100%
Hispanic or Latino
50%
CX-4945
50%
Mammalian Target of Rapamycin (mTOR)
33%
Rapamycin
33%
Leukemia
33%
CK2 Inhibitors
33%
Latino children
33%
Repressor
16%
Tumor Suppressor
16%
Precision Medicine
16%
Combination Treatment
16%
Oncogene
16%
Increased Incidence
16%
Therapeutic Target
16%
Oncoprotein
16%
Protein Kinase CK2
16%
Poor Prognosis
16%
PI3K-AKT-mTOR Pathway
16%
Health Disparities
16%
Transcriptional Repression
16%
Direct Inhibitors
16%
Hematological Malignancies
16%
Reduced Expression
16%
IKZF1
16%
Synergistic Therapeutic Effect
16%
MTOR Protein
16%
Patient-derived Xenograft
16%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Transcription
33%
Mammalian Target of Rapamycin
33%
Kinase
16%
Phosphotransferase
16%
Mechanistic Target of Rapamycin
16%
Repressor
16%
Tumor Suppressor Protein
16%
Oncogene
16%
IKZF1
16%
PI3K/AKT/mTOR Pathway
16%
Health Disparity
16%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Rapamycin
33%
Leukemia
33%
Phosphotransferase
16%
Mammalian Target of Rapamycin
16%
Oncoprotein
16%
Hematologic Malignancy
16%
Therapeutic Effect
16%
Health Disparity
16%
Tumor Suppressor Protein
16%